Nuvectis Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing innovative precision medicines for the treatment of cancer. The company was founded in 2020 and is headquartered in Fort Lee, New Jersey.
Nuvectis' lead product candidate is NXP800, a small molecule drug that is being developed for the treatment of cholangiocarcinoma, a rare and aggressive form of liver cancer. Cholangiocarcinoma is caused by the abnormal growth of cells in the bile ducts. NXP800 is designed to target and kill cancer cells that express a protein called ARID1a.
Nuvectis is currently conducting a Phase 1b clinical trial of NXP800 in patients with cholangiocarcinoma. The company has also initiated a Phase 1b/2 clinical trial of NXP800 in combination with pembrolizumab, a checkpoint inhibitor that is approved for the treatment of several types of cancer.
Nuvectis has raised over $100 million in funding from a number of investors, including NEA, Third Rock Ventures, and Versant Ventures. The company is well-funded and has a strong management team.